BioSpace News Archive

IQVIA Holdings Inc. will announce its second-quarter 2023 financial results before the market opens on Tuesday, August 1, 2023.

Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 101,000 shares of the Company’s common stock to two new employees on July 5, 2023.

The U.S. Food and Drug Administration converted Leqembi, indicated to treat adult patients with Alzheimer’s Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit.

ENDRA Life Sciences Inc., a pioneer of Thermo Acoustic Enhanced UltraSound, announced its 2023 Annual Meeting of Stockholders, which was scheduled to be held this morning, was convened and adjourned, without any business being conducted, due to the lack of the required quorum.

BioSyent Pharma Inc., a subsidiary of BioSyent Inc., is attending the American Head and Neck Society 11th International Conference on Head and Neck Cancer in Montreal, Quebec on July 8-12, 2023 to promote Gelclair®, its new oncology supportive care product.

Quanterix Corporation, a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, announced it has launched LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with the early signs of Alzheimer’s disease.

The Alzheimer’s Association celebrates U.S. Food and Drug Administration action to grant traditional approval of Leqembi™ for the treatment of early Alzheimer’s disease with confirmation of elevated amyloid beta.

Cipla Limited, announced that its wholly-owned subsidiary Cipla US is voluntarily recalling six batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg manufactured in November 2021 to the consumer level.

C2N Diagnostics, a leader in advanced brain health diagnostics, recognizes the landmark decision by the U.S. Food and Drug Administration to approve anti-amyloid antibody lecanemab for intravenous use in the treatment of Alzheimer’s disease.

Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application supporting the traditional approval of LEQEMBI® 100 mg/mL injection for intravenous use, making LEQEMBI the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease.